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DiabetesProhibitin 1 (PHB1), a pleiotropic protein in the cell, has been implicated in the regulation of proliferation,
apoptosis, transcription, mitochondrial protein folding, and as a cell-surface receptor. This diverse array of
functions of PHB1 is attributed to the cell type studied and its subcellular localization. This review discusses
recent data that indicate a diverse role of PHB1 in disease pathogenesis and suggest that targeting PHB1 may
be a potential therapeutic option for treatment of diseases including cancer, inﬂammatory bowel disease,
insulin resistance/type 2 diabetes, and obesity. These diseases are associated with increased oxidative stress
and mitochondrial dysfunction and therefore, the role of PHB1 in both responses will also be discussed.mtDNA, mitochondrial DNA;
lucosamine; PHB1, prohibitin;
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Prohibitin 1 (PHB1) is a 32 kDa protein that belongs to a family of
proteins that share an evolutionarily conserved stomatin/prohibitin/
ﬂotillin/HﬂK/C (SPFH) domain. It is closely related to prohibitin 2
(PHB2), also called B-cell receptor-associated protein 37 (BAP 37) and
repressor of estrogen receptor activity (REA). Prohibitin exhibits a
remarkable degree of sequence conservation across species; the protein
sequences of mouse and rat prohibitin are virtually identical, and these
differ from the human protein sequence by a single amino acid [1].
An N-terminal transmembrane domain consists of a hydrophobic
membrane-anchoring alpha helix (Fig. 1). The prohibitin domain,
characteristic of the SPFH family of proteins, spans amino acid
residues 55–172. This domain has been suggested to be important
for lipid raft associations and protein-protein interactions [2]. A
coiled-coil structure of alpha helices is present at the C-terminal
end of the protein, consisting of amino acids residues 175–252 [2].
A nuclear export sequence consisting of a leucine/isoleucine-rich
motif is present at the C-terminal end, spanning residues 257 to
270 [3]. At the subcellular level, PHB1 has been localized to the cell
membrane and mitochondrial inner membrane complexed to PHB2
[4,5], as well as the cytoplasm, or the nucleus depending on the cell
type and situation [3,6]. In most cell types studied, its predominantlocalization is in the mitochondria. Its subcellular localization
inﬂuences its multiple functions within the cell.
As implied by the name, PHB1 was originally thought to have a
central role in the inhibition of cell-cycle progression. Genetic deletion
of prohibitin is embryonically lethal in mice and ﬂies [7] and the
Drosophila orthologue of PHB1 is essential for normal development
[8]. Although the best-characterized function of the prohibitins is as
chaperones involved in the stabilization of mitochondrial proteins [5],
it has also been implicated in diverse cellular processes including the
regulation of proliferation, apoptosis, and gene transcription [3,6,9].
Recent data have indicated a diverse role of PHB1 in disease
pathogenesis. This review will focus on the potential involvement of
PHB1 in cancer, inﬂammatory bowel disease, insulin resistance/type 2
diabetes, and obesity. Many of these diseases have increased oxidative
stress and mitochondrial dysfunction as common factors, which will
be discussed. The therapeutic potential of targeting PHB1 during
disease will also be discussed.2. Oxidative stress
In most eukaryotic cells, mitochondria are responsible for
providing energy by generating adenosine triphosphate (ATP)
through oxidative phosphorylation and controlling levels of oxidative
stress. During normal function of the mitochondrial respiratory chain,
reactive oxygen species (ROS), which are partially reduced oxygen
species such as superoxide radical (O2−.), hydrogen peroxide (H2O2),
and hydroxyl radical (⋅OH) are generated at low levels. Nitric oxide
(NO) is also generated during normal function of the respiratory chain
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Fig. 1. The functional domains of PHB1.
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(NOO−) is formed by a reaction between superoxide and nitric oxide.
Although most electrons are successfully transferred down the
electron transport chain, up to 10% of the reducing equivalents from
NADH leak to form superoxide radical and hydrogen peroxide, which
diffuse frommitochondria. Approximately 1% of oxygen uptake under
normal physiological conditions is converted to superoxide during
respiration [10]. An elaborate system of neutralizing antioxidant
enzymes, including superoxide dismutase, catalase, glutathione
peroxidase, and antioxidant thiols (glutathione and thioredoxin) are
responsible for consuming superoxide anion and hydrogen peroxide,
thereby preventing their cytotoxic effects under normal conditions.
An imbalance between excessive production of ROS (oxidants) and
impaired protective mechanisms acting to eliminate ROS (antioxidant
defense system) can cause tissue damage, which is deﬁned as
oxidative stress. [11]. An imbalance of oxidants to antioxidants
inﬂuences the redox state of the cells, tissue, and whole organism.
Although oxidants may not always be harmful depending on duration,
intensity and location of the redox imbalance, continued oxidative
stress leads to damage of DNA, lipids, and proteins and can modulate
signal transduction pathways inﬂuencing inﬂammation, apoptosis,
proliferation, repair machinery, and the production of antioxidants.
ROS are potent immunoregulatory and tissue-destructive molecules
associated with the pathophysiology of several diseases including
Parkinson's disease/neurodegeneration, cancer, diabetes mellitus,
obesity and virtually all inﬂammatory diseases including inﬂamma-
tory bowel diseases, all of which are also associated with mitochon-
drial dysfunction which is discussed below [12].
Emerging data suggest that PHB1 plays a role in combating
oxidative stress in multiple cells types. PHB1 levels are decreased
during oxidative stress in intestinal epithelial cells [13] and in ex vivo
lung tissue during hyperoxia [14]. PHB1 knockdown in endothelial
cells increased production of ROS in mitochondria via decreased
activity of complex I and partial blockade of the electron transport
chain [15]. This increase in ROS caused cellular senescence, subse-
quently decreasing cell motility and migration, thereby reducing
endothelial cell angiogenic capacity. In another study by Liu et al. [16],
overexpression of PHB1 in cultured cardiomyocytes protected
mitochondria from injury and apoptosis induced by hydrogen
peroxide and maintained mitochondrial membrane permeability.
Tsutsumi et al. [17] showed that PHB1 interacts with and regulates
assembly of subunits I and IV of cytochrome c oxidase in cultured
hepatocytes. Infection with hepatitis C virus core protein impaired the
interaction of PHB1 with cytochrome c oxidase and subsequently
caused an increase in ROS production during respiration. These results
may explain the reduction of cytochrome c oxidase activity and
increased ROS production in hepatitis C virus infected liver. Studies in
intestinal epithelial cells using in vitro and in vivo models of colitis
suggest that PHB1 protects these cells from oxidative stress that is
associated with the inﬂammatory process [13,18,19]. These studies
are discussed below.
3. Mitochondrial dysfunction
Mitochondrial dysfunction can be characterized by impaired
mitochondrial function, loss of mitochondrial respiratory chain
complexes, mitochondrial DNA (mtDNA) mutations or a decrease in
mtDNA levels, and alterations in mitochondrial membrane potential.ROS can cause mutations in mtDNA and accumulation of such
mutations can inactivate respiratory chain activity and subsequently
cause further increases in mtDNA mutations [20]. This cyclical
progression is thought to contribute to the exponential increases in
oxidative damage and reduced cellular functions noted in aging and
diseases associated with mitochondrial dysfunction such as cancer,
insulin resistance and type 2 diabetes, obesity, inﬂammatory bowel
diseases, Parkinson's disease and neurodegeneration [21–23].
Given that the predominant subcellular localization of PHB1 is in
the mitochondria in most cell types studied to date, emerging data
suggest that PHB1 plays a role in maintaining normal mitochondrial
function and morphology (reviewed in [24]). In yeast, loss of function
of PHB1 leads to an altered mitochondrial morphology, loss of normal
reticular morphology and disorganized mitochondrial distribution
[25]. Similar results are evident in mammalian cells. Complexes of
PHB1 and PHB2 in the inner membrane of mitochondria control
cristae morphogenesis and the processing of the dynamin-like GTPase
optic atrophy 1 (OPA1) (reviewed in [26]). OPA1 is required for
mitochondrial fusion and cristae maintenance. Loss of PHB2 and
subsequent disruption of PHB1/PHB2 complexes in mouse embryonic
ﬁbroblasts (MEFs) or HeLa cells causes accumulation of fragmented
mitochondria and loss of OPA1 expression [27]. These results were
corroborated in cancer cell lines expressing PHB1-directed shRNAs
[28]. Furthermore, knockdown of PHB1 in HeLa cells caused
disorganization of mitochondrial nucleoids and a 30% reduction of
mtDNA copy number, indicative of mitochondrial dysfunction [29]. It
remains less clear whether PHB1 expression maintains the mitochon-
drial membrane potential; knockdown of PHB1 in endothelial cells
[15] and knockdown of PHB2 and subsequent disruption of PHB1/
PHB2 complexes in MEFs [27] depolarized mitochondrial membrane
potential, whereas in HeLa cells and cancer cell lines mitochondrial
membrane potential was maintained despite knockdown of PHB1
[28,29]. Overexpression of PHB1 protected cardiomyocytes from
hypoxia-induced decrease in mitochondrial membrane potential [30].
Despite opposing results in regards to mitochondrial membrane
potential, it is clear that PHB1 plays a critical role in maintaining
normal mitochondrial function and morphology, but the mechanism
has yet to be determined. Studies in yeast have suggested that the
major function of PHB1 is that of a chaperone for imported proteins in
mitochondria, protecting newly imported proteins from degradation
by the m-AAA protease [26]. It has been shown that PHB1 interacts
with complex I and subunits of cytochrome c oxidase of the
respiratory chain and regulates their assembly [15,17]. It is therefore
conceivable that loss of PHB1 in mitochondria could lead to
accelerated proteolysis of membrane proteins and impair function
of the mitochondrial respiratory chain. One obvious effect of
respiratory chain dysfunction is increased oxidant production leading
to oxidative stress, which can cause alterations in mitochondrial
morphology and membrane potential.
4. Cancer
PHB1 plays a critical role in the regulation of cell cycle
progression and can inhibit DNA replication in multiple cell types
[25,31–35]. PHB1 levels are increased in cancers of the cervix [36],
esophagus [37], stomach [38–40], breast [41], lung [42], bladder
[43], thyroid [44], ovary [45], and prostrate [46], whereas levels are
decreased in gliomas [47]. Consensus binding sites for the
oncoprotein Myc are present in the PHB1 promoter and likely
contributes to the increased PHB1 levels in many tumors [32].
Serum levels of PHB1 are increased in cancer patients compared to
normal controls [48,49]. Although somatic mutations in the PHB1
gene were observed in a few sporadic breast cancers, none were
identiﬁed in the ovary, liver or lung cancers examined [41,50]. The
role of PHB1 in cancer cell proliferation and/or tumor suppression
remains controversial especially since PHB1 expression is increased
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reported depending upon the type of tissue involved and data that
suggest a pro-tumorigenic versus an anti-tumorigenic role are
discussed below. Fig. 2 depicts PHB1 involvement in inﬂuencing
tumorigenesis.
The ﬁrst studies indicating that PHB1 plays a role in tumor
suppression in breast cancer actually showed that this effect was
attributable to the 3′ untranslated region of the PHB1 gene which
encodes a functional RNA that blocks transition between the G1 and
S phases of the cell cycle, thereby arresting cell proliferation [51–53].
However, further studies in breast and prostate cancer cell lines
indicate that a portion of PHB1 is localized in the nucleus and
interacts with and regulates the tumor suppressors p53 and Rb in
steroid-responsive cells. PHB1 co-localizes with p53 in breast
carcinoma cell lines and its binding to p53 increases p53 transcrip-
tional activity via increased DNA binding [54]. It was also shown that
PHB1 is degraded during Skp2B overexpression in breast cancer lines
and this subsequently causes attenuation of p53 activity in vivo and
in vitro [55]. These results suggest that PHB1 is required for maximal
p53 transcriptional activity and may play a critical role in p53
checkpoint control of the cell cycle. PHB1 has also been shown to
interact with the retinoblastoma tumor suppressor protein (Rb) and
its family members, p107 and p130, in the nucleus [56]. The Rb
family suppresses growth via binding to and inhibiting the E2F
family of transcription factors. PHB1 was shown to repress E2F-
mediated transcription function via its interaction with Rb and
histone deacetylase activity [6] as well as the recruitment of the
ATP-dependent nucleosome remodeling complexes containing Brg-1
and Brm [57]. These ﬁndings suggest that PHB1 may suppress tumor
growth by regulating transcription.
Further support exists for the anti-tumorigenic role of PHB1 in
prostate cancer [58], gastric cancer [59], and liver cancer [60].
Overexpression of PHB1 arrested prostate tumor growth while
knockdown using siRNA accelerated tumor growth, even in castratedPlasma
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Fig. 2. Simpliﬁed model of the opposing roles of PHB1 in tumorigenesis. Subcellular
localization of PHB1 may dictate its role in tumorigenesis and cell fate. A) Activated Ras
directly interacts with plasma membrane-bound PHB1, causing the activation of C-Raf.
The Ras-Raf pathway is involved in cell growth and transformation [62]. B) PHB1
interacts with the tumor suppressor Rb in the nucleus, thereby suppressing E2F-
mediated transcription [6,56]. C) Nuclear PHB1 interacts with p53, resulting inmaximal
p53 transcriptional activity and p53 check point control of the cell cycle [54,55].mice lacking androgen signaling [58]. Liu et al. reported that PHB1
levels were reduced in gastric adenocarcinoma [59], which opposes
previous ﬁndings showing an increase in PHB1 [38–40]. Liu et al.
reported that PHB1 is a target of microRNA-27a, which is upregulated
in gastric cancer and reduces PHB1 levels in vivo. They suggest that
down-regulation of PHB1 bymiR-27amay explain why suppression of
miR-27a can inhibit gastric cancer cell growth. A recent study by Ko et
al. [60], support a tumor suppressor role of PHB1 in hepatocytes. Mice
with hepatocyte-speciﬁc deletion of PHB1 exhibited liver injury,
ﬁbrosis, oxidative stress and hepatocellular carcinoma developing by
8 months of age. Mitochondrial abnormalities are evident by 3 weeks
of age including no cristae formation.
Despite the evidence that PHB1 has anti-tumorigenic properties,
there are a number of studies as well indicating a pro-tumorigenic role
of PHB1. PHB1 was shown to be necessary for activation of C-Raf by the
oncogene Ras in HeLa cells [61]. Ras was shown to directly interactwith
PHB1 leading to C-Raf activation and was required for Ras-induced cell
migration. The authors speculate that PHB1 may play a role of a
chaperone or membrane anchor for C-Raf to interact with Ras [62].
These results suggest that PHB1 may have a prominent role in the
progression ofmalignant transformation. Furthermore, in a recent study
using cultured cancer cell lines, PHB1-directed shRNAs reduced
proliferation and the ability to exhibit anchorage-independent growth
[28]. In chemoresistant ovarian cancer cells, PHB1 expression was
associated with drug-resistance [63] and silencing of PHB1 expression
increased the sensitivity of the cells to apoptosis [45].
Such opposing results regarding the role of PHB1 in tumorigenesis
may be explained by its subcellular localization. Indeed, the
subcellular localization of PHB1 has been shown to affect cell fate,
speciﬁcally apoptosis [3]. Although many studies have reported that
levels of PHB1 are increased in many types of tumors, only a handful
of reports describe its subcellular localization. Patel et al. [63] found
that PHB1 levels were increased on the cell surface of chemoresistant
cells compared to chemosensitive cells. Similarly, studies showing
PHB1 interaction with C-Raf induced by Ras oncogene found PHB1 in
the caveolin-1-rich fractions of the plasma membrane of HeLa cells
[61]. These studies suggest that increased expression of PHB1 on the
plasma membrane may facilitate tumorigenesis. However, studies
showing PHB1 interaction with the tumor suppressors p53 and Rb
also describe a signiﬁcant portion of PHB1 presiding in the nucleus. In
this regard, increased levels of PHB1 as seen in many types of cancer
may act in an anti-tumorigenic role, especially if the levels of PHB1 are
increased in the nucleus. Further studies need to elucidate the
intracellular localization of PHB1 during the progression of normal
tissue to carcinoma. Targeting speciﬁc subsets of cellular PHB1 may
have therapeutic potential; reducing plasma membrane PHB1 and/or
increasing nuclear PHB1maymodulate tumor progression. Also, PHB1
can translocate from the nucleus to the cytoplasm upon induction of
apoptosis [3]. C-Raf bound to PHB is recruited to the plasma
membrane by RAS [62]. It remains unknown whether PHB1 can
translocate to or from the mitochondria or from the cytoplasm into
the nucleus. Re-locating the portion of PHB1 from the cell surface to
the nucleusmay also affect tumor outcome by localizing the protein to
the organelle where it may elicit its tumor suppressing functions.
5. Inﬂammatory bowel disease
Oxidative stress associated with inﬂammatory diseases originates
predominately from immune cells mounting an immune response to
bacteria, fungi, or other antigens. Neutrophils andmacrophages, when
stimulated by bacterial products or antigen, undergo a respiratory
burst via the activation of membrane-bound NAPDH oxidase,
releasing super oxide and hydrogen peroxide. Neutrophils and
macrophages also release the enzyme myeloperoxidase, constituting
5% of their total protein load, which metabolizes hydrogen peroxide
and chloride ion to form hypochlorous acid, commonly known as
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Fig. 3. Cartoon representation of PHB1 in intestinal epithelial cells. In IBD, a chronic and
exaggerated immune response ensues during which activated immune cells and
intestinal epithelial cells release ROS and immunoregulatory cytokines including TNFα.
ROS causes oxidative stress, leading to increased permeability and damage. Altered
epithelial barrier function allows translocation of antigen/bacteria from the intestinal
lumen to the lamina propria. TNFα activates the transcription factor NF-κB which can
stimulate proinﬂammatory signaling and increase permeability. In intestinal epithelial
cells PHB1 levels are decreased during inﬂammation. Restoration of PHB1 levels in
these cells indicate that it inhibits oxidative stress and activation of NF-κB. NF-κB,
nuclear factor-kappa B; TNFα, tumor necrosis factor alpha; TNFR, tumor necrosis factor
receptor; ROS, reactive oxygen species.
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thought to be 100–1000 times more toxic than superoxide radical or
hydrogen peroxide and is critical in the oxygen-dependent micro-
bicidal activity of phagocytes. Excessive release of oxidants and
generation of myeloperoxidase-derived oxidants causes tissue dam-
age characteristic of inﬂammatory diseases.
The most common inﬂammatory bowel diseases (IBD), Crohn's
disease and ulcerative colitis, are associated with increased ROS and
decreased antioxidant enzymes in the intestinal mucosa [65–68]. A
number of key antioxidants such as glutathione and thioredoxin levels
are decreased during inﬂammation [69,70]. Animals with genetic
manipulation of enzymes involved in oxidative defense pathways
exhibit increased susceptibility to the development of colitis and
transgenic mice with overexpression of certain antioxidant enzymes
are protected from the development of colitis [71–73]. In IBD, ROS
have been demonstrated to play a pathophysiologic role in barrier
dysfunction, apoptosis, and wound healing [74–76]. Importantly, the
levels of ROS have been correlated to clinical and endoscopic
assessment of severity of disease [77]. In addition, oxidative stress-
induced p53 inactivation and DNA damage in the setting of chronic
inﬂammation has been associated with the risk of IBD-associated
colon cancer [78]. Since PHB1 has been shown to modulate p53
activation [54,55], it is of interest to determine whether PHB1 plays a
role in the transition of dysplasia to cancer in the colon.
Not surprisingly, there has been considerable interest in develop-
ing antioxidant-based therapeutic strategies for the treatment of IBD.
Commonly used drugs, in particular sulfasalazine and its activemoiety
5-aminosalicylic acid, are potent ROS scavengers (reviewed by Miles
and Grisham [79]). Only two past studies have been published using
therapies speciﬁcally to combat oxidative stress; high positive
response rates (N80% remission) were observed when patients with
severe Crohn's disease (n=30) or ulcerative colitis (n=4) were
treated with free or liposomal-encapsulated bovine Cu/Zn-superoxide
dismutase [80,81]. However, the therapeutic applicability of natural
antioxidant enzymes has restrictions in terms of limited cell
permeability, short circulating half-life, immunogenicity and cost of
production. In addition, these therapies target single pathways and
given the complexity of the oxidant response, targeting single
pathways may not be efﬁcient in combating oxidative stress in IBD.
Thus, there is an unmet need for designing potent antioxidant based
treatment strategies in IBD.
Studies in intestinal epithelial cells using in vitro models of
oxidative stress/inﬂammation and in vivo models of colitis suggest
that PHB1 protects these cells from inﬂammation-associated oxida-
tive stress and may modulate the inﬂammatory process (Fig. 3). Cell-
surface associated PHB1 in intestinal epithelial cells binds to Vi
polysaccharide of Salmonella typhi and inhibits the inﬂammatory
response to S. typhi infection [4]. PHB1 mRNA and protein levels are
decreased in inﬂamedmucosa during IBD [13,82] and in experimental
models of colitis [13]. Tumor necrosis factor alpha (TNFα), a key
cytokine that plays a central role in IBD, decreases PHB1 mucosal
levels in vivo and in cultured intestinal epithelial cells [83]. These
results suggest that TNFα may contribute to the reduced levels of
prohibitin in the mucosa of IBD patients. Exogenous expression of
PHB1 in intestinal epithelial cells reduced the activation of the nuclear
factor-kappa B (NF-κB) pathway, which plays a central role in
inﬂammatory responses and also regulates transcription of multiple
cytokines [83]. Collectively, these results suggest that PHB1 may be
crucial in modulating intestinal inﬂammatory processes.
Restoration of PHB1 levels in intestinal epithelial cells during
inﬂammation was achieved using transgenic overexpression in mice
[19], adenovirus infection and nanoparticle delivery [18]. Transgenic
mice overexpressing PHB1 under the control of the villin promoter
showed restored levels of PHB1 in the intestinal epithelium during
colitis induced by dextran sodium sulfate and Salmonella typhimurium.
Compared to wild-type littermates, PHB1 transgenic mice exhibiteddecreased oxidative stress and colitis and sustained activation of the
antioxidant nuclear factor erythroid 2-related factor 2 (Nrf2), a
transcriptional regulator of antioxidant responses [19]. As a proof-of-
principle to demonstrate the therapeutic efﬁcacy of PHB1 for human
IBD, adenovirus-directed administration by enema and nanoparticle-
based colonic delivery of biologically active PHB1 were tested in mice
during experimental colitis [18]. Both methods of delivery resulted in
increased levels of PHB1 in the surface epithelial cells of the colon and
reduced severity of dextran sodium sulfate-induced colitis as measured
by body weight loss, clinical score, myeloperoxidase activity, pro-
inﬂammatory cytokine expression, and histological score. Mice treated
with PHB1 delivered by adenovirus or nanoparticle also showed
reduced protein carbonyl content, a marker of oxidative stress [18].
Collectively, these results suggest that PHB1 acts as a regulator of
antioxidant response in intestinal epithelial cells and that restoration of
PHB1 levels represents a potential therapeutic approach in IBD.6. Insulin resistance/type 2 diabetes
It is well established that insulin resistance increases the chance of
developing type 2 diabetes. Mitochondrial dysfunction is thought to
contribute to the development of insulin resistance and type 2 diabetes.
Alcoholism is a type 2 diabetes risk factor [84]. In pancreatic β-cells,
ethanol increases oxidative stress, subsequently causing cell injury,
mitochondrial dysfunction, apoptosis and the inhibition of insulin
secretion [85–87]. In a study by Lee et al. [88], PHB1 overexpression
prevented pancreatic β-cell apoptosis induced by ethanol treatment.
These results were further recapitulated by incubation of cultured
pancreatic β-cells with exogenous PHB1. Knockdown of PHB1 using
siRNA enhanced ethanol-induced apoptosis in these cells. Upon ethanol
treatment, PHB1 protein level increased and localized to the mitochon-
dria after export from the nucleus. These results suggest that PHB1
Table 1
The role and therapeutic potential of prohibitin in disease.
PHB1 function Cell type Subcellular localization Disease Potential therapeutic strategy Reference
Combat oxidative stress Pancreatic β-cells Mitochondria/nucleus Type 2 diabetes Increase PHB1 levels [88]
Intestinal epithelial cells Mitochondria IBD Increase PHB1 levels [13,19]
Cardiomyocytes Mitochondria Myocardium injury Increase PHB1 levels [16]
Hepatocytes Mitochondria Hepatitis C virus Restore PHB1 function [17]
Activate p53 and modulate Rb
tumor suppressors
Cancer cell lines (T47D, MCF7, SW13,
C33A, Ramos)
Nucleus Cancer Increase nuclear PHB1 levels [54–56]
c-Raf activation by Ras oncogene HeLa Plasma membrane Cancer Decrease cell surface PHB1 [61]
Vascular receptor Adipose vasculature Plasma membrane Obesity Target PHB1 [92,93]
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could be a potential target for diabetes treatment.
An opposing study by Vessal et al. [89] showed that PHB1 added to
ﬁbroblasts or adipocytes inhibits insulin-stimulated glucose and fatty
acid oxidation. These results suggest that PHB1would inhibit glucose-
induced insulin secretion which is dependent on glucose oxidation.
Perhaps the effect of PHB1 is cell type speciﬁc and therefore, the effect
of PHB1 on glucose oxidation warrants further investigation.
Recent studies by Mishra and Ande et al. have explored the
O-linked β-N-acetylglucosamine (O-GlcNAc) posttranslational modiﬁ-
cation of mitochondrial proteins, including PHB1, in response to insulin
and high glucose [44,90]. An increase in O-GlcNAcylation of various
proteins correlates with the development of insulin resistance [91].
O-GlcNAcylation is likely important for normal mitochondrial function
and PHB1 is O-GlcNAc modiﬁed under basal conditions [90]. O-GlcNAc
modiﬁcationwas shown tomodulate tyrosine phosphorylation of PHB1
in response to insulin. Furthermore, O-GlcNAcylation and tyrosine
phosphorylation of PHB1 was increased by exposing cells to high
glucose [44]. These studies suggest an association between posttrans-
lational modiﬁcations (O-GlcNAcylation and phosphorylation) of PHB1
and the cellular response to insulin and glucose. Further studies are
needed to determine whether changes in O-GlcNAcylation and
phosphorylation of PHB1 are associatedwithmitochondrial dysfunction
and insulin resistance/type 2 diabetes.
7. Obesity
Deﬁcient PHB1 activity in the liver contributes to the progression of
non-alcoholic steatohepatitis and obesity although the mechanism
remains unknown [9]. Kolonin et al. [92] reported the ﬁrst study
identifying PHB1 as a marker of adipose vasculature. They found that
plasma membrane-bound PHB1 acts as a vascular receptor in
subcutaneous and peritoneal white fat for a proapoptotic peptide
resulting in weight loss and prevention of obesity in mice. Internaliza-
tion of the peptide by PHB1 caused fat resorption, apoptosis of white fat
vasculature, and improved glucose tolerance and serum insulin levels.
Hossen et al. [93] recently showed that a similar adipose-speciﬁc
peptide delivered using a nanocarrier was internalized by cell-surface
PHB1 and blocking PHB1 using an anti-prohibitin antibody prevented
this uptake. Drugs targeted to PHB1, which is also expressed in the
vasculature of human white fat, may be a therapeutic option for the
treatment of obesity.
8. Concluding remarks
The potential of PHB1 to interact with tumor suppressor proteins
and transcription factors, inhibit oxidative stress and mitochondrial
dysfunction, act as a cell-surface receptor for the vasculature of
adipose tissue, and modulate cell proliferation and apoptosis, suggest
that PHB1 harbors great potential for the development of therapeutic
agents for obesity, diabetes, cancer and inﬂammatory diseases.
Depending upon the disease state, therapeutic potential exists in
altering the levels of PHB1 expressed in affected cells, such as indiabetes or inﬂammation, altering the subcellular localization of PHB1
expression, such as in cancer, or targeting cell surface PHB1, such as in
obesity (Table 1). The multiple functions of PHB1 are only beginning
to be elucidated, but it is clear this protein provides new avenues for
therapeutic-based research.Acknowledgements
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